{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"23.4","value":"13.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Kaplan-Meier estimate of disease progression rate. Disease progression is determined by Response Evaluation Criteria in Solid Tumours criteria (RECIST). RECIST criteria is described here: http://ctep.cancer.gov/protocolDevelopment/docs/recist\\_guideline.pdf","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.","id":"OG000","title":"Imatinib Mesylate"}],"paramType":"NUMBER","populationDescription":"All eligible patients.","reportingStatus":"POSTED","timeFrame":"From registration to two years","title":"Rate of Disease Progression at 2 Years","type":"PRIMARY","unitOfMeasure":"percentage of participants"}